Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Anthrax

Anthrax

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Anthrax

8 trials tracked for Anthrax: 2 in phase 3 or 4 and 1 with published results.

8Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 5 Phase 1 1
  1. Phase 3 VELOCITY: An Anthrax Vaccine Clinical Study Completed
  2. Phase 3 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Completed
  3. Phase 2 A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Completed
  4. Phase 2 Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) Completed
  5. Phase 2 BARDA Securing Anthrax Immunity For the Elderly Completed
  6. Phase 2 Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study Completed
Show 2 more trials
  1. Phase 2 Ciprofloxacin BioThrax Co-Administration Study Completed
  2. Phase 1 Anthrax AV7909 Liquid vs Lyophilized Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Anthrax: what the trials found

Clinical trials have evaluated multiple interventions for anthrax, including the vaccine candidate AV7909 and the established vaccine BioThrax. In large-scale Phase 3 studies of AV7909, high rates of seroconversion were observed; specifically, approximately 64.4% to 68.9% of participants achieved a TNA NF50 ≥0.56 by Day 64 across different lots 1. Additionally, Phase 1 and Phase 2 trials for AV7909 confirmed significant seroconversion rates for both TNA NF50 and Anti-PA IgG [6, 8].

BioThrax has been evaluated across multiple phases of clinical trials. In Phase 3 studies, the percentage of subjects achieving a predefined TNA response threshold varied by time point, with results ranging from approximately 49.5% to 76.7% at Day 63 2. Further Phase 2 evaluations of BioThrax confirmed its use in anthrax prophylaxis and treatment contexts [4, 7].

Recent results — preliminary, needs further review

  • Ciprofloxacin 500mg tablets were evaluated in a Phase 2 trial; however, results regarding TNA NF50 values are not yet corroborated 3.
  • AIGIV 3.5 mg/kg was investigated in a Phase 2 trial but remains unconfirmed 5.

For the clinician treating this condition

  • AV7909 demonstrates high seroconversion rates for TNA NF50 and Anti-PA IgG, making it a robust candidate for anthrax immunization [1, 8].
  • BioThrax is an established intervention with documented TNA response thresholds in multiple clinical trials [2, 4, 7].

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Updated guidelines issued for anthrax prevention and treatment
Infectious Disease
Updated guidelines issued for anthrax prevention and treatment What are the latest guidelines for preventing and treating anthrax?
A guideline publication presents updated recommendations for anthrax prevention and treatment.
New official guidelines now update how doctors prevent and treat anthrax, ensuring medical teams have the latest rules for protecting people…
CDC Apr 5, 2026
Anthrax outbreak reported in sheep on Texas farm during winter months
Infectious Disease
Anthrax outbreak reported in sheep on Texas farm during winter months Anthrax outbreak reported in Texas sheep during winter months
A field report describes an anthrax outbreak in sheep on a Texas farm during winter, which is unusual for the disease's typical seasonal pat…
An unexpected anthrax outbreak occurred in Texas sheep during winter, a season when the disease is not typically active.
CDC Apr 4, 2026
CDC issues recommendations for anthrax vaccine use in the United States
Allergy & Immunology
CDC issues recommendations for anthrax vaccine use in the United States Health officials issue updated recommendations for anthrax vaccine use
The CDC has published recommendations and reports regarding the use of anthrax vaccine in the United States.
Health officials updated anthrax vaccine guidelines to clarify when doctors should recommend the shot for prevention.
CDC Apr 4, 2026

Questions about Anthrax

What are the current CDC recommendations for anthrax vaccines?

The CDC recommends the anthrax vaccine for people at high risk of exposure, such as laboratory workers, and for post-exposure protection in specific situations, while noting that supply is limited.

Full answer →
What does the CDC recommend regarding anthrax vaccine use in the US?

The CDC recommends the anthrax vaccine for specific high-risk groups like military personnel and first responders, with updated schedules allowing boosters every three years for some people.

Full answer →
What are the updated guidelines for anthrax prevention and treatment?

Updated CDC guidelines from 2023 provide preferred and alternative antibiotics and antitoxins for preventing and treating anthrax, including specific advice for limited resources or resistant bacteria.

Full answer →